Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Helen Tesfaye"'
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-12 (2024)
Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reporte
Externí odkaz:
https://doaj.org/article/a409dae7b8d64bffbc67fb3a8cee406b
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-2 (2024)
Externí odkaz:
https://doaj.org/article/1b45064e466d4e25abc84ea3e931b788
Autor:
Daniel H Solomon, Robert J Glynn, Niteesh K Choudhry, Julie C Lauffenburger, Elliott M Antman, Su Been Lee, Helen Tesfaye, Angela Tong
Publikováno v:
BMJ Open, Vol 13, Iss 11 (2023)
Objective Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sou
Externí odkaz:
https://doaj.org/article/ea3708e7ec0d49e3ab4121ede648a5bc
Publikováno v:
Ophthalmology Retina. 6:1145-1153
To investigate the cardiovascular (CV) safety associated with intravitreal anti-VEGF injections (IAVIs) in patients with diabetic retinopathy (DR).Population-based cohort study using Medicare and 2 commercial insurance claims databases in the United
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::794a5790f3524644426345fb06a0dd30
https://doi.org/10.1016/j.oret.2022.06.010
https://doi.org/10.1016/j.oret.2022.06.010
Autor:
Norbert Pötschke, Phyo Than Htoo, Helen Tesfaye, Julie M. Paik, Deborah Wexler, Mehdi Najafzadeh, Robert J Glynn, Anouk Déruaz-Luyet, Soulmaz Fazeli Farsani, Lisette Koeneman, Sebastian Schneeweiss, Elisabetta Patorno
Publikováno v:
Diabetologie und Stoffwechsel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99d1ebe62ff6823df6b885f26af12208
https://doi.org/10.1055/s-0043-1767943
https://doi.org/10.1055/s-0043-1767943
Autor:
Richeek, Pradhan, Elisabetta, Patorno, Helen, Tesfaye, Sebastian, Schneeweiss, Hui, Yin, Jessica, Franklin, Ajinkya, Pawar, Christina, Santella, Oriana H Y, Yu, Christel, Renoux, Laurent, Azoulay
Publikováno v:
Am J Epidemiol
Case reports and a pharmacovigilance analysis have linked glucagon-like peptide 1 receptor agonists (GLP-1 RAs) with anaphylactic reactions, but real-world evidence for this possible association is lacking. Using databases from the United Kingdom (Cl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89df69f9f9e240e83d87180f943aae3f
https://doi.org/10.1093/aje/kwac021
https://doi.org/10.1093/aje/kwac021
Autor:
Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Seoyoung C. Kim, Mehdi Najafzadeh, Lisette Koeneman, Soulmaz Fazeli Farsani, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Publikováno v:
JAMA network open. 5(10)
ImportanceLimited evidence is available on the comparative effectiveness of empagliflozin vs alternative second-line glucose-lowering agents in patients with type 2 diabetes (T2D) receiving routine care who have a broad spectrum of cardiorenal risk.O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3c384e1a6685ef507ee2b6ced9db540
https://pubmed.ncbi.nlm.nih.gov/36264574
https://pubmed.ncbi.nlm.nih.gov/36264574
Autor:
Laurent Azoulay, Elisabetta Patorno, Sebastian Schneeweiss, Robert W. Platt, Lysanne Campeau, Oriana H.Y. Yu, Blanaid Hicks, Seanna Vine, Huimin Yin, Helen Tesfaye, Devin Abrahami
Objective: To determine whether sodium-glucose co-transporter 2 (SGLT2) inhibitors, compared with glucagon-like peptide-receptor agonists (GLP-1RAs) or dipeptidyl peptidase-4 (DPP4) inhibitors are associated with an increased risk of early bladder ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8719f0d5295affe61d83425d37bdaee2
https://doi.org/10.2337/figshare.21040987
https://doi.org/10.2337/figshare.21040987
Autor:
DEVIN ABRAHAMI, HELEN TESFAYE, HUI YIN, ORIANA HOI YUN YU, ROBERT W. PLATT, SEBASTIAN SCHNEEWEISS, ELISABETTA PATORNO, LAURENT AZOULAY
Publikováno v:
Diabetes. 71
SGLT2 inhibitors (SGLT2is) have been shown to reduce the risk of cardiovascular and mortality events in large cardiovascular outcome trials in patients with type 2 diabetes. However, their safety profile is controversial, with some trials reporting i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b032c61c5584115b4286a420aacbb90
https://doi.org/10.2337/db22-1146-p
https://doi.org/10.2337/db22-1146-p